These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1178 related items for PubMed ID: 22088934

  • 1. Development of inflammatory bowel disease during anti-TNF-α therapy for inflammatory rheumatic disease: a nationwide series.
    Toussirot É, Houvenagel É, Goëb V, Fouache D, Martin A, Le Dantec P, Dernis E, Wendling D, Ansemant T, Berthelot JM, Bader-Meunier B, Kantelip B, Le CRI.
    Joint Bone Spine; 2012 Oct; 79(5):457-63. PubMed ID: 22088934
    [Abstract] [Full Text] [Related]

  • 2. Differences in the incidence of flares or new onset of inflammatory bowel diseases in patients with ankylosing spondylitis exposed to therapy with anti-tumor necrosis factor alpha agents.
    Braun J, Baraliakos X, Listing J, Davis J, van der Heijde D, Haibel H, Rudwaleit M, Sieper J.
    Arthritis Rheum; 2007 May 15; 57(4):639-47. PubMed ID: 17471540
    [Abstract] [Full Text] [Related]

  • 3. Is it safe to use anti-TNF-α agents for tuberculosis in children suffering with chronic rheumatic disease?
    Kilic O, Kasapcopur O, Camcioglu Y, Cokugras H, Arisoy N, Akcakaya N.
    Rheumatol Int; 2012 Sep 15; 32(9):2675-9. PubMed ID: 21789614
    [Abstract] [Full Text] [Related]

  • 4. [Autoimmune aspects of treatment with TNF-alpha inhibitors].
    Kolarz B, Targońska-Stepniak B, Darmochwał-Kolarz D, Majdan M.
    Postepy Hig Med Dosw (Online); 2007 Aug 28; 61():478-84. PubMed ID: 17786135
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Costs of tumor necrosis factor blockers per treated patient using real-world drug data in a managed care population.
    Schabert VF, Watson C, Joseph GJ, Iversen P, Burudpakdee C, Harrison DJ.
    J Manag Care Pharm; 2013 Oct 28; 19(8):621-30. PubMed ID: 24074008
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Emerging role of anti-tumor necrosis factor therapy in rheumatic diseases.
    Kalden JR.
    Arthritis Res; 2002 Oct 28; 4 Suppl 2(Suppl 2):S34-40. PubMed ID: 12110156
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Paradoxical adverse events of anti-tumour necrosis factor therapy for spondyloarthropathies: a retrospective study.
    Fouache D, Goëb V, Massy-Guillemant N, Avenel G, Bacquet-Deschryver H, Kozyreff-Meurice M, Ménard JF, Muraine M, Savoye G, Le Loët X, Tharasse C, Vittecoq O.
    Rheumatology (Oxford); 2009 Jul 28; 48(7):761-4. PubMed ID: 19395543
    [Abstract] [Full Text] [Related]

  • 11. TNF alpha inhibition as treatment modality for certain rheumatologic and gastrointestinal diseases.
    Wiedmann MW, Mössner J, Baerwald C, Pierer M.
    Endocr Metab Immune Disord Drug Targets; 2009 Sep 28; 9(3):295-314. PubMed ID: 19594416
    [Abstract] [Full Text] [Related]

  • 12. Do Anti-TNF Agents Increase the Risk of Inflammatory Bowel Disease Evolution in Patients with Ankylosing Spondylitis? Real Life Data.
    Üsküdar Cansu D, Üsküdar Teke H, Temel T, Ertürk A, Kahraman O, Korkmaz C.
    J Natl Med Assoc; 2019 Jun 28; 111(3):262-269. PubMed ID: 30389147
    [Abstract] [Full Text] [Related]

  • 13. Clinical and economic burden of extra-articular manifestations in ankylosing spondylitis patients treated with anti-tumor necrosis factor agents.
    Gao X, Wendling D, Botteman MF, Carter JA, Rao S, Cifaldi M.
    J Med Econ; 2012 Jun 28; 15(6):1054-63. PubMed ID: 22563743
    [Abstract] [Full Text] [Related]

  • 14. Development of Crohn's disease following anti-tumour necrosis factor therapy (etanercept).
    Yazisiz V, Avci AB, Erbasan F, Yildirim B, Terzioğlu E.
    Colorectal Dis; 2008 Nov 28; 10(9):953-4. PubMed ID: 18294265
    [Abstract] [Full Text] [Related]

  • 15. Psoriatic skin lesions induced by tumor necrosis factor antagonist therapy: clinical features and possible immunopathogenesis.
    Collamer AN, Battafarano DF.
    Semin Arthritis Rheum; 2010 Dec 28; 40(3):233-40. PubMed ID: 20580412
    [Abstract] [Full Text] [Related]

  • 16. Retention on anti-tumour necrosis factor therapy: the Waikato experience.
    Ip K, Hartley L, Solanki K, White D.
    N Z Med J; 2015 May 29; 128(1415):34-40. PubMed ID: 26117510
    [Abstract] [Full Text] [Related]

  • 17. Effectiveness and safety of adalimumab in patients with ankylosing spondylitis or psoriatic arthritis and history of anti-tumor necrosis factor therapy.
    Rudwaleit M, Van den Bosch F, Kron M, Kary S, Kupper H.
    Arthritis Res Ther; 2010 May 29; 12(3):R117. PubMed ID: 20553600
    [Abstract] [Full Text] [Related]

  • 18. Tumour necrosis factor inhibitors.
    Nash PT, Florin TH.
    Med J Aust; 2005 Aug 15; 183(4):205-8. PubMed ID: 16097922
    [Abstract] [Full Text] [Related]

  • 19. [Biologicals in the treatment of rheumatic diseases].
    Scherer HU, Burmester GR.
    Dtsch Med Wochenschr; 2006 Oct 13; 131(41):2279-85. PubMed ID: 17036270
    [No Abstract] [Full Text] [Related]

  • 20. TNFalpha antagonist continuation rates in 442 patients with inflammatory joint disease.
    Brocq O, Roux CH, Albert C, Breuil V, Aknouche N, Ruitord S, Mousnier A, Euller-Ziegler L.
    Joint Bone Spine; 2007 Mar 13; 74(2):148-54. PubMed ID: 17368068
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 59.